Ratings Neuren Pharmaceuticals Limited

Equities

NEU

NZNEUE0001S8

Delayed Australian S.E. Other stock markets 09:03:43 2024-05-07 pm EDT			5-day change	1st Jan Change
20.24 ^AUD	-0.07%		+6.22%	-18.92%

Apr. 24	Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments	MT
Apr. 23	Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 27.27 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
NEUREN PHARMACEUTICALS LIMITED	-18.92%	1.68B	D+
ELI LILLY AND COMPANY	+33.43%	690B	C+
NOVO NORDISK A/S	+26.43%	546B	B
JOHNSON & JOHNSON	-5.12%	358B	C+
MERCK & CO., INC.	+19.59%	323B	B-
ABBVIE INC.	+4.89%	287B	C+
ASTRAZENECA PLC	+14.32%	235B	B+
NOVARTIS AG	+5.79%	199B	B-
ROCHE HOLDING AG	-9.49%	195B	A+
AMGEN INC.	+4.26%	161B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes